Literature DB >> 17876002

Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

B Henrichfreise1, I Wiegand, W Pfister, B Wiedemann.   

Abstract

In this study, we analyzed the mechanisms of multiresistance for 22 clinical multiresistant and clonally different Pseudomonas aeruginosa strains from Germany. Twelve and 10 strains originated from cystic fibrosis (CF) and non-CF patients, respectively. Overproduction of the efflux systems MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM was studied. Furthermore, loss of OprD, alterations in type II topoisomerases, AmpC overproduction, and the presence of 25 acquired resistance determinants were investigated. The presence of a hypermutation phenotype was also taken into account. Besides modifications in GyrA (91%), the most frequent mechanisms of resistance were MexXY-OprM overproduction (82%), OprD loss (82%), and AmpC overproduction (73%). Clear differences between strains from CF and non-CF patients were found: numerous genes coding for aminoglycoside-modifying enzymes and located, partially in combination with beta-lactamase genes, in class 1 integrons were found only in strains from non-CF patients. Furthermore, multiple modifications in type II topoisomerases conferring high quinolone resistance levels and overexpression of MexAB-OprM were exclusively detected in multiresistant strains from non-CF patients. Correlations of the detected phenotypes and resistance mechanisms revealed a great impact of efflux pump overproduction on multiresistance in P. aeruginosa. Confirming previous studies, we found that additional, unknown chromosomally mediated resistance mechanisms remain to be determined. In our study, 11 out of 12 strains and 3 out of 10 strains from CF patients and non-CF patients, respectively, were hypermutable. This extremely high proportion of mutator strains should be taken into consideration for the treatment of multiresistant P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876002      PMCID: PMC2151423          DOI: 10.1128/AAC.00148-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids.

Authors:  M M Ochs; M P McCusker; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Detection of VIM-2 metallo-beta-lactamase in Pseudomonas aeruginosa from Germany.

Authors:  Beate Henrichfreise; Irith Wiegand; Kimberley J Sherwood; Bernd Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa.

Authors:  T Köhler; M Michéa-Hamzehpour; U Henze; N Gotoh; L K Curty; J C Pechère
Journal:  Mol Microbiol       Date:  1997-01       Impact factor: 3.501

4.  Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  S Jalal; B Wretlind
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

5.  Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa.

Authors:  K Poole; N Gotoh; H Tsujimoto; Q Zhao; A Wada; T Yamasaki; S Neshat; J Yamagishi; X Z Li; T Nishino
Journal:  Mol Microbiol       Date:  1996-08       Impact factor: 3.501

6.  Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa.

Authors:  Mara L Sobel; Shadi Neshat; Keith Poole
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

7.  Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study.

Authors:  H Vahaboglu; R Oztürk; G Aygün; F Coşkunkan; A Yaman; A Kaygusuz; H Leblebicioglu; I Balik; K Aydin; M Otkun
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa.

Authors:  N Masuda; N Gotoh; S Ohya; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa.

Authors:  T Mine; Y Morita; A Kataoka; T Mizushima; T Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  68 in total

1.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Chronic respiratory infections by mucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem.

Authors:  Carlos Juan; Olivia Gutiérrez; Feliu Renom; Margarita Garau; Carmen Gallegos; Sebastián Albertí; José Luis Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 5.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

6.  Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.

Authors:  Bridgette L Therriault; John W Wilson; Jason N Barreto; Lynn L Estes
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

7.  The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa.

Authors:  Huseyin Agah Terzi; Canan Kulah; Ihsan Hakkı Ciftci
Journal:  World J Microbiol Biotechnol       Date:  2014-06-26       Impact factor: 3.312

8.  Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.

Authors:  Alina D Gutu; Nicole Sgambati; Pnina Strasbourger; Mark K Brannon; Michael A Jacobs; Eric Haugen; Rajinder K Kaul; Helle Krogh Johansen; Niels Høiby; Samuel M Moskowitz
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

9.  Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Thomas Krahn; Christie Gilmour; Justin Tilak; Sebastien Fraud; Nicholas Kerr; Calvin Ho-Fung Lau; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Authors:  Xavier Mulet; María D Maciá; Ana Mena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.